PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
BCAB BioAtla
- 0.465
- +0.029+6.56%
Close Feb 14 16:00 ET
- 0.470
- +0.005+1.16%
Post 20:01 ET
26.96MMarket Cap-0.27P/E (TTM)
0.501High0.420Low1.71MVolume0.441Open0.436Pre Close776.27KTurnover3.43%Turnover RatioLossP/E (Static)58.02MShares4.02052wk High1.17P/B23.26MFloat Cap0.38052wk Low--Dividend TTM50.07MShs Float76.630Historical High--Div YieldTTM18.52%Amplitude0.380Historical Low0.452Avg Price1Lot Size
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
BioAtla Stock Forum
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treat...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown ...
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Mee...
*Buys: $Shift4 Payments (FOUR.US)$ , $Molina Healthcare (MOH.US)$ , $Hudson Pacific Properties Inc (HPP.US)$ , $Olaplex (OLPX.US)$ , $BioAtla (BCAB.US)$
*Adds: $Baidu (BIDU.US)$ , $Alibaba (BABA.US)$
*Reduced: $JD.com (JD.US)$ , $TheRealReal (REAL.US)$
*Sold: $HCA Healthcare (HCA.US)$ , $Citigroup (C.US)$ $Sprott Physical Gold Trust (PHYS.US)$ , $Block (SQ.US)$ , $Cigna Group (CI.US)$ , $Advance Auto Parts (AAP.US)$ , $BP PLC (BP.US)$ , ...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
No comment yet